NY-UNITED-FIRST-PARTNERS
1.10.2018 13:47:05 CEST | Business Wire | Press release
United First Partners (“UFP”), a leading independent Equity Research, Advisory and Brokerage firm, providing event driven and special situations equities research and execution, adds four analysts in London and New York.
UFP has hired Bruno Burki, as a London based research salesperson. Prior to joining UFP, Bruno was head of event driven research at Square Global Markets and previously a senior Associate in the UK M&A team at Barclays in London, where he advised corporates and financial sponsors on a wide range of strategic transactions. Bruno notably advised ENOC in their acquisition of the minorities’ stake they didn't own in Dragon Oil, and International Power in their defence against GDF.
In addition, UFP hired Patryk Basiewicz (CFA) as a special situations analyst. Patryk joined UFP from Olivetree where he was a TMT Sector Strategist. At Olivetree, Patrick was responsible for formulation of investment ideas in European TMT equity space and handled fundamental aspects of Olivetree’s Event-driven product. Previous roles include buyside analyst positions as well as management consultant at McKinsey & Co.
The London unit also hired Josh Rosen as a special situations analyst. Prior to joining UFP, Josh was an Investment Banking Associate at Citigroup in London in the FIG group, where he worked on large-cap M&A deals across the banking and insurance sectors, as well as IPOs and capital markets financing. Prior to this, Josh held roles in Wealth & Investment Management at Citigroup and Barclays in London and Geneva where he advised Ultra High Net Worth clients.
In New York, UFP reinforced its research team with the hiring of Maggie Bishop. She joins UFP from Wells Fargo Securities in Houston where she was an Analyst in the Energy Investment Banking Group, involved in a wide variety of mergers and acquisitions, capital markets financings and strategic advisory assignments for clients across the upstream, midstream, and oilfield services sectors.
United First Partners CEO Stephane Mardel commented: “One of UFP group’s key strength is the delivery of unique, actionable and thorough research work across the globe. With the hiring of Bruno, Patryk, Josh and Maggie, UFP continues to offer one of the largest special situations research platform on the street, with diversified talents, covering multiple industries. These new hires help complement the skills of our existing established research teams in London and New York, demonstrating our commitment to producing top tier special situations research, and our desire to work relentlessly to maximise value for our clients.”
About UFP and Mariana UFP
United First Partners is an independent global financial services firm, with a strong reputation and leading position in the Equities and Derivatives space. UFP’s award winning research reflects UFP’s commitment to excellence in Special Situations Research, providing best in class and in-depth research coverage on companies where specific events may act as a catalyst for material price actions, using fundamental analysis and unique in-house legal resources. United First Partners and Mariana entered into a strategic alliance in May 2017 to generate synergies across the group’s complementary business lines and play an active role in the industry consolidation. Mariana UFP offers comprehensive cross-asset services in Europe & Australia (through Mariana UFP LLP, regulated by the FCA), in North America (through United First Partners LLC, SEC regulated and member of FINRA and SIPC) and in the UAE (through UFP Capital Markets (DIFC) Limited, regulated by the DFSA). The Mariana UFP group also offers structured products, advisory and asset management services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181001005471/en/
Contact:
United First Partners Stephane Mardel +442030174330 stephane.mardel@utdfirst.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom